<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this study was to evaluate the incidence of <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> after percutaneous implantation of a port-catheter system via the left subclavian artery for hepatic arterial infusion chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>In 90 patients with inoperable <z:hpo ids='HP_0002896'>liver cancer</z:hpo>, a port-catheter system was implanted via the left subclavian artery </plain></SENT>
<SENT sid="2" pm="."><plain>In 5 patients (5.6%) <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> occurred after port-catheter implantation </plain></SENT>
<SENT sid="3" pm="."><plain>In one patient (1.1%) <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> formed around the catheter, as confirmed by autopsy </plain></SENT>
<SENT sid="4" pm="."><plain>The risk of <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> should be taken into consideration when a trans-left subclavian arterial access route is used for the percutaneous implantation of a port-catheter system for hepatic arterial infusion chemotherapy </plain></SENT>
</text></document>